Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.
(2013) In British Journal of Cancer 108(11). p.2321-2328- Abstract
- Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced... (More)
- Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3804795
- author
- Boman, Karolina LU ; Larsson, Anna H LU ; Segersten, U ; Kuteeva, E ; Johannesson, Henrik ; Nodin, Björn LU ; Eberhard, Jakob LU ; Uhlén, M ; Malmström, P-U and Jirström, Karin LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Cancer
- volume
- 108
- issue
- 11
- pages
- 2321 - 2328
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000320249500016
- pmid:23652315
- scopus:84884185522
- pmid:23652315
- ISSN
- 1532-1827
- DOI
- 10.1038/bjc.2013.215
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000), Oncology, MV (013035000)
- id
- 59451232-9eb4-425f-8401-661993b0f9fa (old id 3804795)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23652315?dopt=Abstract
- date added to LUP
- 2016-04-01 10:07:38
- date last changed
- 2024-01-06 08:19:59
@article{59451232-9eb4-425f-8401-661993b0f9fa, abstract = {{Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com.}}, author = {{Boman, Karolina and Larsson, Anna H and Segersten, U and Kuteeva, E and Johannesson, Henrik and Nodin, Björn and Eberhard, Jakob and Uhlén, M and Malmström, P-U and Jirström, Karin}}, issn = {{1532-1827}}, language = {{eng}}, number = {{11}}, pages = {{2321--2328}}, publisher = {{Nature Publishing Group}}, series = {{British Journal of Cancer}}, title = {{Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.}}, url = {{http://dx.doi.org/10.1038/bjc.2013.215}}, doi = {{10.1038/bjc.2013.215}}, volume = {{108}}, year = {{2013}}, }